Meeting NewsVideo

VIDEO: Sustained-release dexamethasone implant puts compliance in surgeon’s hands

PARIS — At the European Society of Cataract and Refractive Surgeons meeting, John A. Hovanesian, MD, speaks about the advantages of using sustained-release Dextenza (Ocular Therapeutix) to treat pain and inflammation after cataract surgery. Dextenza is designed to go in the lower lid punctum and slowly release dexamethasone in the tear film over 1 month, thus eliminating compliance issues for patients who would otherwise use steroid eye drops postoperatively. Data from three FDA clinical trials are now available.

PARIS — At the European Society of Cataract and Refractive Surgeons meeting, John A. Hovanesian, MD, speaks about the advantages of using sustained-release Dextenza (Ocular Therapeutix) to treat pain and inflammation after cataract surgery. Dextenza is designed to go in the lower lid punctum and slowly release dexamethasone in the tear film over 1 month, thus eliminating compliance issues for patients who would otherwise use steroid eye drops postoperatively. Data from three FDA clinical trials are now available.

    See more from European Society of Cataract and Refractive Surgeons Meeting